Loading stock data…
XAIR
$0.51-0.01 (-2.13%)
Market ClosedLast close May 1
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Beyond Air, Inc. in the Healthcare sector is trading at $0.51. The stock is currently near its 52-week low of $0.43, remaining 67.9% below its 200-day moving average. Technical signals show neutral RSI of 38 and bullish MACD crossover, explaining why XAIR maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 38) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.51
Potential Upside
5%
Whystock Fair Value$0.54
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos....
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.68M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.53
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-382.21%
Volume
Today's trading volume
127,198
Recent News
Beyond Air Inc (XAIR) Expands Focus on Nitric Oxide Therapies
Beyond Air Inc (NASDAQ:XAIR) is among the best NASDAQ penny stocks to buy according to analysts. On February 20, Beyond Air Inc (NASDAQ:XAIR) commented that it was pleased with a review article that recognized the potential of high-dose nitric oxide as a potential therapy for respiratory illnesses. The peer-reviewed article appeared in a journal of […]
How The Narrative On Beyond Air (XAIR) Is Resetting Around LungFit PH And Delayed Approval
The consensus fair value estimate for Beyond Air has shifted from US$12.33 to US$8.67, signaling a reset in how analysts are framing potential upside. Bulls point to the second generation LungFit PH system and a clearer, though extended, regulatory path as reasons they still see room for upside. Bears, on the other hand, view the lower targets as reflecting a longer and more uncertain route to meaningful sales. As you read on, you will see how these differing views are shaping the evolving...
Beyond Air Inc (XAIR) Q3 2026 Earnings Call Highlights: Impressive Revenue Growth and Strategic ...
Beyond Air Inc (XAIR) reports a 105% revenue increase and significant cost reductions, while navigating ongoing financial challenges and FDA approval processes.
Beyond Air, Inc. Q3 2026 Earnings Call Summary
Moby summary of Beyond Air, Inc.'s Q3 2026 earnings call
Top Midday Decliners
TryHard (THH) unveiled on Wednesday an equity purchase agreement in which Summer Explorer Investment